Relay Therapeutics, Inc.
NASDAQ:RLAYBiotechnology
+$0.41 today
- Market cap
- $3.65B
- Beta
- 1.75
- P/E (TTM)
- -10.5
- EPS (TTM)
- -$1.52
Volume 2.43M
Average 3.70M
RLAY Total Liabilities
Everything the company owes to creditors and other parties.
Relay Therapeutics, Inc.NASDAQ: RLAY
Total Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total liabilities rises 22.6% from a year ago
Total liabilities stood at $77.45M at the end of Q2 FY2026, up 22.6% from a year earlier and up 34.9% from the prior quarter. Over 3 fiscal years it compounded at -28.7% a year.
Context
- Total liabilities amounted to 8.0% of total assets at the end of Q2 FY2026, down 0.7 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +22.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 54.27M USD
- Year-over-year change
- -42.0%
- 4-year CAGR
- -16.3%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 54.27M | -42.0% |
| FY2024 | 2024-12-31 | 93.5M | +1.7% |
| FY2023 | 2023-12-31 | 91.98M | -38.5% |
| FY2022 | 2022-12-31 | 149.55M | +35.2% |
| FY2021 | 2021-12-31 | 110.64M | — |
Total Liabilities vs competitors
How RLAY compares with its peers on the latest reported figures
- RLAY's Jun 2026 total liabilities of $77.45M is the 6th highest of the 11 companies compared; the peer median is $70.83M.
- Its year-over-year change of +22.6% is the 6th highest of 11, against a peer median of +22.2%.
- Total liabilities amounts to 8.0% of total assets for RLAY, versus a peer median of 8.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.72B | +204.3% | +78.7% | 39.7% | |
| Aug 2026 | $226.99M | +51.1% | +9.7% | 19.0% | |
| Jun 2026 | $139.85M | -12.4% | +13.0% | 8.5% | |
| Mar 2026 | $93.08M | +21.7% | +30.9% | 9.0% | |
| Sep 2026 | $82.2M | +13.4% | -11.7% | 8.2% | |
| Jun 2026 | $77.45M | +22.6% | -28.7% | 8.0% | |
| Mar 2026 | $59.46M | +56.1% | +42.6% | 49.7% | |
| Sep 2026 | $53.29M | +6.4% | -34.5% | 5.2% | |
| Mar 2026 | $25.32M | +95.4% | +45.8% | 7.2% | |
| Mar 2026 | $24.47M | +22.7% | +41.0% | 5.9% | |
| Mar 2026 | $21.21M | -8.3% | -1.7% | 4.9% | |
| Peer median (excluding RLAY) | $70.83M | +22.2% | +22.0% | 8.4% | |
Competitors are the stored peer set for RLAY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 280.12M | 151.79M | 143.74M | 124.29M | 84.02M |
| Short-term Investments | 677.95M | 847.12M | 606.35M | 657.04M | 470.5M |
| Net Receivables | 4.94M | 5.22M | 0 | 0 | 0 |
| Inventory | 0 | 12.11M | 0 | 0 | 0 |
| Other Current Assets | 1.76M | 3.26M | 3.32M | 10.53M | 5.97M |
| Total Current Assets | 976.24M | 1.02B | 770.1M | 809.2M | 578.28M |
| Property, Plant & Equipment (Net) | 27.32M | 75.39M | 68.87M | 57.67M | 41.72M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 2.3M | 2.3M | 2.3M | 2.3M | 0 |
| Long-term Investments | 0 | 2.58M | 2.71M | 0 | 1.34M |
| Tax Assets | 0 | (2.58M) | 0 | 0 | 0 |
| Other Non-current Assets | 2.58M | 2.58M | 0 | 2.12M | 0 |
| Total Non-current Assets | 32.2M | 80.27M | 73.88M | 62.09M | 43.05M |
| Total Assets | 1.01B | 1.1B | 843.98M | 871.3M | 621.33M |
| Account Payables | 8.28M | 10.58M | 9.21M | 14.1M | 7.71M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 248K | 0 | 0 | 7.68M | 0 |
| Other Current Liabilities | 989K | 26.15M | 1.91M | 2.1M | 463K |
| Total Current Liabilities | 24.32M | 63.71M | 30.27M | 50.73M | 25.58M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 65.26M | 32.38M | 13.21M | 0 | 0 |
| Total Non-current Liabilities | 86.31M | 85.84M | 61.71M | 42.78M | 28.69M |
| Total Liabilities | 110.64M | 149.55M | 91.98M | 93.5M | 54.27M |
| Common Stock | 109K | 121K | 127K | 168K | 168K |
| Retained Earnings | (768.1M) | (1.06B) | (1.4B) | (1.74B) | (2.01B) |
| Accumulated OCI | (1.09M) | (10.42M) | (196K) | (991K) | 733K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 897.81M | 950.22M | 752M | 777.79M | 567.06M |
| Total Debt | 22.9M | 57.74M | 53.47M | 48.5M | 32.46M |
| Net Debt | (257.22M) | (94.05M) | (90.27M) | (75.79M) | (51.56M) |
Relay Therapeutics, Inc.
NASDAQ:RLAY
Intrinsic Alpha fair value
Locked
Current Price
$16.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.